The article discusses the results of a study which examined the effectiveness of cangrelor, a reversible intravenous platelet inhibitor, in percutaneous coronary interventions (PCI). The study showed that the odds of the primary outcome was reduced by 19 percent by cangrelor compared with 4.7 percent for control and 41 percent for stent thrombosis. It concluded that cangrelor reduced PCI periprocedural thrombotic complications at the expense of increased bleeding. INSET: Panel: Research in context.